Study designed to evaluate the effect of significant ERM on the visual and anatomic outcomes of intravitreal anti-VEGF therapy for eAMD.
Gass in 1987 described three cases of epiretinal membrane (ERM) associated with wet macular degeneration. Since then we have seen that is not rare to find the coexistence of these entities. An ERM may produce intrinsic disorganization of the outer retina leading to persistent increased macular thickness and/or edema. This persistent edema may affect the effectiveness in the treatment of exudative age-related macular degeneration (eAMD). Therefore, this study was designed to evaluate the effect of significant ERM on the visual and anatomic outcomes of intravitreal anti-VEGF therapy for eAMD.
Study Type
OBSERVATIONAL
Enrollment
16
Best corrected visual acuity
Evaluate the best visual acuity during the follow up.
Time frame: 12 months
Central macular thickness
Evaluation of the retinal thickness changes with anti-VEGF treatment
Time frame: 12 months
Fluorescein angiogram
Evaluation of changes in lesion size during follow-up.
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.